A recent study was finished earlier than planned due to high patient interest and strong investigator engagement. The company is set to begin the Biologics License Application process in the third quarter of 2026, following the accelerated approval pathway, with a potential approval expected in the second half of 2027. The company is located in Rockville, Maryland, and the update was released on June 24, 2026.